GlassScriptPhysician profile
Sharon M Wesley
NPI 1821066887
$4,178.10
in general payments reported to CMS, 2019-2025
29 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $530 · 2021: $381 · 2022: $560 · 2023: $885 · 2024: $719 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $512.78 | 2019-2024 | Trelegy Ellipta, Nucala |
| Abbvie INC. | $477.38 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Amgen INC. | $445.76 | 2019-2023 | Otezla, Repatha, Tezspire |
| Lilly USA, LLC | $298.85 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.67 | 2022-2025 | Trintellix |
| Novo Nordisk INC | $218.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $192.15 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $164.41 | 2020-2022 | |
| Mylan Specialty L.P. | $155.54 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $152.63 | 2022-2024 | Xarelto |
| Pfizer INC. | $145.49 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $139.17 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $124.16 | 2023-2024 | |
| Allergan, INC. | $117.29 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $113.63 | 2022-2023 | Freestyle Libre 3 |
| Therapeuticsmd, INC. | $66.53 | 2019-2020 | |
| Dexcom, INC. | $52.00 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.48 | 2024-2025 | Cologuard Collection Kit |
| Heartflow, INC. | $30.14 | 2024 | |
| Alfasigma USA, INC. | $27.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.43 | 2020 | |
| Exeltis, USA INC. | $23.87 | 2024 | Slynd |
| Insmed, INC. | $22.85 | 2024 | Arikayce |
| Novartis Pharmaceuticals Corporation | $22.75 | 2019 | |
| Irhythm Technologies, INC. | $21.62 | 2024 | Zio Monitor, Zio Xt Patch |
| Idorsia Pharmaceuticals US INC | $19.48 | 2023 | Quviviq |
| Cleerly, INC. | $14.06 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Cranial Technologies, INC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Wesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.